Choice of Drug for Malaria Prevention During Pregnancy Does Not Affect Infant Serologic Responses to <i>Plasmodium falciparum</i> Erythrocyte Membrane Proteins 1

While sulfadoxine-pyrimethamine has been the primary drug in intermittent preventive treatment in pregnancy, dihydroartemisinin-piperaquine (DP) is being considered as an alternative. DP may lead to lower antimalarial antibodies in the mother, resulting in higher risk of malaria in infancy. We probed cord blood sera collected from women enrolled in a clinical trial of sulfadoxine-pyrimethamine vs DP on a protein microarray containing diverse <i>Plasmodium falciparum</i> erythrocyte membrane proteins 1 to measure the impact of intermittent preventive treatment in pregnancy on proteins associated with malaria disease susceptibility. These results suggest that effective maternal malaria prevention may not alter the susceptibility of infants to malaria.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-01-23
DOI
https://doi.org/10.1093/ofid/ofaf037
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Choice of Drug for Malaria Prevention During Pregnancy Does Not Affect Infant Serologic Responses to Plasmodium falciparum Erythrocyte Membrane Proteins 1

Omid Taghavian, Philip L. Felgner, Don P. Mathanga, Mark A. Travassos et al.
Open Forum Infectious Diseases
Malaria Research and Control
article

Choice of Drug for Malaria Prevention During Pregnancy Does Not Affect Infant Serologic Responses to Plasmodium falciparum Erythrocyte Membrane Proteins 1

Omid Taghavian, Philip L. Felgner, Don P. Mathanga, Mark A. Travassos, Miriam K. Laufer, Jobiba Chinkhumba, Ankur Sharma, Matthew Adams, L Andronescu, Algis Jasinskas, Aarti Jain, Rie Nakajima, Amed Ouattara
article en

Abstract

While sulfadoxine-pyrimethamine has been the primary drug in intermittent preventive treatment in pregnancy, dihydroartemisinin-piperaquine (DP) is being considered as an alternative. DP may lead to lower antimalarial antibodies in the mother, resulting in higher risk of malaria in infancy. We probed cord blood sera collected from women enrolled in a clinical trial of sulfadoxine-pyrimethamine vs DP on a protein microarray containing diverse <i>Plasmodium falciparum</i> erythrocyte membrane proteins 1 to measure the impact of intermittent preventive treatment in pregnancy on proteins associated with malaria disease susceptibility. These results suggest that effective maternal malaria prevention may not alter the susceptibility of infants to malaria.

Open Forum Infectious DiseasesVol. 12(2)
University of Maryland, Baltimore (US), University of California, Irvine (US), Kamuzu Central Hospital (MW), Kamuzu University of Health Sciences (MW)
National Institutes of Health
Good health and well-being
Openalex Percentile: Top 98%
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Choice of Drug for Malaria Prevention During Pregnancy Does Not Affect Infant Serologic Responses to <i>Plasmodium falciparum</i> Erythrocyte Membrane Proteins 1 — Omid Taghavian, Philip L. Felgner, et al. · Open Forum Infectious Diseases (2025) | TGRS Research Map | TGRS